Women and MDMA: particularities of gender and sex

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorCAREZZATO, Fabio
dc.contributor.authorARRUDA, Ilana Falcao de
dc.contributor.authorFIGUEIREDO, Caio Petrus Monteiro
dc.contributor.authorCASTALDELLI-MAIA, Joao Mauricio
dc.date.accessioned2024-04-05T19:37:21Z
dc.date.available2024-04-05T19:37:21Z
dc.date.issued2023
dc.description.abstractThis comprehensive review delves into the intricate interplay between gender/sex and MDMA use, drawing upon recent evidence. It explores how girls, as a means of coping with negative emotions, often resort to drug use, while boys primarily initiate drug use due to peer pressure or sensation-seeking tendencies. Women, frequently having endured traumatic life events, may turn to MDMA as a form of self-medication. Notably, women face an elevated risk of contracting sexually transmitted infections due to their altered mental states and diminished condom use during MDMA consumption. Additionally, females exhibit heightened sensitivity to the subjective effects of MDMA, consistently reporting heightened anxiety, adverse effects, and negative side effects. While women may have a higher susceptibility to hyponatremia, intriguingly, they appear to be less vulnerable to MDMA-induced hyperthermia. Although limited, available data suggest that prenatal MDMA exposure could lead to motor delays in infants, necessitating further research to unravel the potential cognitive effects. Furthermore, MDMA-assisted psychotherapy holds immense promise for addressing post-traumatic stress disorder (PTSD) among female subgroups. These pronounced gender and sex disparities in MDMA use and its effects underscore the pressing need for additional research to develop tailored, effective, and safe treatment approaches that account for these fundamental factors.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexScopus
dc.description.indexDimensions
dc.description.indexWoS
dc.identifier.citationINTERNATIONAL REVIEW OF PSYCHIATRY, v.35, n.5-6, Special Issue, p.461-467, 2023
dc.identifier.doi10.1080/09540261.2023.2250867
dc.identifier.eissn1369-1627
dc.identifier.issn0954-0261
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/59112
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTDeng
dc.relation.ispartofInternational Review of Psychiatry
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright TAYLOR & FRANCIS LTDeng
dc.subject3,4-Methylenedi-oxy-methamphetamineeng
dc.subjectwomeneng
dc.subjectsubstance use disordereng
dc.subjectgendereng
dc.subject.otherecstasyeng
dc.subject.wosPsychiatryeng
dc.titleWomen and MDMA: particularities of gender and sexeng
dc.typearticleeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcFABIO CAREZZATO
hcfmusp.contributor.author-fmusphcILANA FALCAO DE ARRUDA
hcfmusp.contributor.author-fmusphcCAIO PETRUS MONTEIRO FIGUEIREDO
hcfmusp.contributor.author-fmusphcJOAO MAURICIO CASTALDELLI MAIA
hcfmusp.description.beginpage461
hcfmusp.description.endpage467
hcfmusp.description.issue5-6
hcfmusp.description.issueSpecial Issue
hcfmusp.description.volume35
hcfmusp.origemWOS
hcfmusp.origem.dimensionspub.1163496556
hcfmusp.origem.pubmed38299658
hcfmusp.origem.scopus2-s2.0-85168656268
hcfmusp.origem.wosWOS:001080218600001
hcfmusp.publisher.cityABINGDONeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceBaggott MJ, 2016, ADV PHARMACOL SCI, V2016, DOI 10.1155/2016/2175896eng
hcfmusp.relation.referenceBarenys M, 2020, NEUROTOXICOLOGY, V78, P209, DOI 10.1016/j.neuro.2019.12.007eng
hcfmusp.relation.referenceBasedow LA, 2022, ADDICT SCI CLIN PRAC, V17, DOI 10.1186/s13722-022-00329-yeng
hcfmusp.relation.referenceDurdle H, 2008, DEPRESS ANXIETY, V25, P241, DOI 10.1002/da.20297eng
hcfmusp.relation.referenceFonsart J, 2009, TOXICOL APPL PHARM, V241, P339, DOI 10.1016/j.taap.2009.09.008eng
hcfmusp.relation.referenceFonseca F, 2021, CURR ADDICT REP, V8, P89, DOI 10.1007/s40429-021-00357-9eng
hcfmusp.relation.referenceGreen AR, 2004, EUR J PHARMACOL, V500, P3, DOI 10.1016/j.ejphar.2004.07.006eng
hcfmusp.relation.referenceHoldcroft A, 2007, J ROY SOC MED, V100, P2, DOI 10.1258/jrsm.100.1.2eng
hcfmusp.relation.referenceHysek CM, 2014, SOC COGN AFFECT NEUR, V9, P1645, DOI 10.1093/scan/nst161eng
hcfmusp.relation.referenceIllingworth BJG, 2021, J PSYCHOPHARMACOL, V35, P501, DOI 10.1177/0269881120965915eng
hcfmusp.relation.referenceIncera-Fernández D, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19116387eng
hcfmusp.relation.referenceKandall SR, 2010, J ADDICT DIS, V29, P117, DOI 10.1080/10550881003684491eng
hcfmusp.relation.referenceKirkpatrick MG, 2014, PSYCHOPHARMACOLOGY, V231, P3899, DOI 10.1007/s00213-014-3528-zeng
hcfmusp.relation.referenceKostick KM, 2018, CULT HEALTH SEX, V20, P1071, DOI 10.1080/13691058.2018.1475682eng
hcfmusp.relation.referenceLiechti ME, 2005, SWISS MED WKLY, V135, P652eng
hcfmusp.relation.referenceMcElrath K, 2005, SUBST USE MISUSE, V40, P1461, DOI 10.1081/JA-200066814eng
hcfmusp.relation.referenceMoritz ML, 2013, NEPHROL DIAL TRANSPL, V28, P2206, DOI 10.1093/ndt/gft192eng
hcfmusp.relation.referenceMüller F, 2019, NEUROSCI BIOBEHAV R, V96, P10, DOI 10.1016/j.neubiorev.2018.11.004eng
hcfmusp.relation.referenceNational Institute on Drug Abuse, 2020, Substance use in women research reporteng
hcfmusp.relation.referenceNational Institute on Drug Abuse, 2016, SUBST US WOMeng
hcfmusp.relation.referenceNeff M, 2018, DEVIANCE SOC, V42, P569, DOI 10.3917/ds.423.0569eng
hcfmusp.relation.referenceReneman L, 2001, LANCET, V358, P1864, DOI 10.1016/S0140-6736(01)06888-Xeng
hcfmusp.relation.referenceRigg KK, 2020, SOC WORK PUBLIC HLTH, V35, P282, DOI 10.1080/19371918.2020.1781013eng
hcfmusp.relation.referenceSimmler LD, 2011, J CLIN ENDOCR METAB, V96, P2844, DOI 10.1210/jc.2011-1143eng
hcfmusp.relation.referenceSinger LT, 2016, NEUROTOXICOL TERATOL, V54, P22, DOI 10.1016/j.ntt.2016.01.003eng
hcfmusp.relation.referenceSinger LT, 2012, PEDIATRICS, V130, P407, DOI 10.1542/peds.2012-0666eng
hcfmusp.relation.referenceSmid MC, 2019, CLIN OBSTET GYNECOL, V62, P168, DOI 10.1097/GRF.0000000000000418eng
hcfmusp.relation.referenceStuderus E, 2021, J PSYCHOPHARMACOL, V35, P556, DOI 10.1177/0269881121998322eng
hcfmusp.relation.referenceUnited Nations Office on Drugs and Crime (UNODC), 2022, World Drug Report 2022, booklet 4, Drug market trends: Cocaine, Amphetamine-type stimulants [Internet]eng
hcfmusp.relation.referenceVizeli P, 2017, J PSYCHOPHARMACOL, V31, P576, DOI 10.1177/0269881117691569eng
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublication6f6e5a7d-a3e9-4f2c-a8eb-7d51676e91f9
relation.isAuthorOfPublicationa1507ea8-81c9-4d8e-be44-b67f425dac74
relation.isAuthorOfPublication5b05c944-8365-446d-9deb-97aab219244c
relation.isAuthorOfPublication6f026b82-161c-477a-b929-8c741fe9efff
relation.isAuthorOfPublication.latestForDiscovery6f6e5a7d-a3e9-4f2c-a8eb-7d51676e91f9
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - HC/IPer